These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 31112617

  • 1. Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study.
    Zuidema S, Desar IME, van Erp NP, Kievit W.
    Br J Clin Pharmacol; 2019 Sep; 85(9):1994-2001. PubMed ID: 31112617
    [Abstract] [Full Text] [Related]

  • 2. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany.
    Tamoschus D, Draexler K, Chang J, Ngai C, Madin-Warburton M, Pitcher A.
    Clin Drug Investig; 2017 Jun; 37(6):525-533. PubMed ID: 28361439
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK.
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: a systematic review and economic evaluation.
    Hislop J, Quayyum Z, Elders A, Fraser C, Jenkinson D, Mowatt G, Sharma P, Vale L, Petty R.
    Health Technol Assess; 2011 Jun; 15(25):1-178. PubMed ID: 21689502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours.
    Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng W, Finkelstein S, Demetri G.
    Clin Drug Investig; 2007 Jun; 27(2):85-93. PubMed ID: 17217313
    [Abstract] [Full Text] [Related]

  • 9. Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation.
    Wilson J, Connock M, Song F, Yao G, Fry-Smith A, Raftery J, Peake D.
    Health Technol Assess; 2005 Jul; 9(25):1-142. PubMed ID: 15985189
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sunitinib for the treatment of metastatic gastrointestinal stromal tumors: the effect of TDM-guided dose optimization on clinical outcomes.
    Giraud EL, Westerdijk K, van der Kleij MBA, Guchelaar NAD, Meertens M, Bleckman RF, Rieborn A, Mohammadi M, Roets E, Mathijssen RHJ, Huitema ADR, Koolen SLW, Gelderblom H, Moes DJAR, Reyners AKL, Touw DJ, Keizer-Heldens P, Oosten AW, van der Graaf WTA, Steeghs N, van Erp NP, Desar IME, Dutch Pharmacology Oncology Group (DPOG).
    ESMO Open; 2024 Jun; 9(6):103477. PubMed ID: 38833964
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.
    JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140
    [Abstract] [Full Text] [Related]

  • 15. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
    Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P.
    JAMA Oncol; 2020 Aug 01; 6(8):1241-1246. PubMed ID: 32469385
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M, Deutsch JM.
    Curr Clin Pharmacol; 2015 Aug 01; 10(4):311-20. PubMed ID: 26548908
    [Abstract] [Full Text] [Related]

  • 18. Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors for Patients with Advanced Gastrointestinal Stromal Tumors.
    Nerich V, Fleck C, Chaigneau L, Isambert N, Borg C, Kalbacher E, Jary M, Simon P, Pivot X, Blay JY, Limat S.
    Clin Drug Investig; 2017 Jan 01; 37(1):85-94. PubMed ID: 27665470
    [Abstract] [Full Text] [Related]

  • 19. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
    Goulooze SC, Galettis P, Boddy AV, Martin JH.
    Cancer Chemother Pharmacol; 2016 Jul 01; 78(1):209-16. PubMed ID: 27295055
    [Abstract] [Full Text] [Related]

  • 20. A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology.
    Erku D, Schneider J, Scuffham P.
    Pharmacol Res Perspect; 2021 Oct 01; 9(5):e00862. PubMed ID: 34546005
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.